NDA 218710 · Phathom Pharmaceuticals INC
Voquezna
Vonoprazan Fumarate · Oral
Last checked: Nov 20, 2026Latest source record: Jul 17, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jul 17, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
132
24 Phase 3, 29 recruiting
FAERS reports
8,132
5,240 serious, 1,069 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 17, 2024 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval LetterLabelReview
2 products under this application
- VOQUEZNA · VONOPRAZAN FUMARATE EQ 10MG BASE · TABLET, ORAL · Prescription
- VOQUEZNA · VONOPRAZAN FUMARATE EQ 20MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vonoprazan" as an intervention, any sponsor and status, largest first.
- The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS PatientsPivotal-lookingRecruiting
Qilu Hospital of Shandong UniversityAcademic, hospital or other
NCT04728516 · 2,600 participants (planned) · Start Apr 12, 2023 · Primary completion Jun 30, 2026
Drug: Vonoprazan-based dual eradication therapy for two weeks; amoxicillin and 1 more · For: Acute Coronary Syndrome; Helicobacter Pylori Infection
Sites: Bozhou, China; Chuzhou, China; Hefei, China · 42 sites in all
- Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori EradicationPivotal-lookingStatus unknown
Xijing Hospital of Digestive DiseasesAcademic, hospital or other
NCT06168214 · 1,404 participants (planned) · Start Sep 4, 2023 · Primary completion Nov 25, 2024
Drug: Rabeprazloe+bismuth+amoxicillin+clarithromycin; Vonoprazan+amoxicillin+clarithromycin 14 days and 7 more · For: the Eradication Rates of Helicobacter Pylori
Sites: Xi'an, China
- Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 DaysPivotal-lookingStatus unknown
Shandong UniversityAcademic, hospital or other
NCT04901117 · 1,300 participants (planned) · Start Jun 2021 · Primary completion Jun 2023
Drug: Amoxicillin; Clarithromycin and 5 more · For: Helicobacter Pylori Infection
Sites: Jinan, China
- Bismuth-containing Quadruple Therapy for Helicobacter Pylori EradicationPivotal-lookingCompleted
Shandong UniversityAcademic, hospital or other
NCT05049902 · 1,300 participants · Start Sep 21, 2021 · Primary completion May 30, 2023
Drug: Amoxicillin; Clarithromycin and 5 more · For: Helicobacter Pylori Infection
Sites: Nanjing, China; Dezhou, China; Heze, China · 6 sites in all
- Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori InfectionPivotal-lookingRecruiting
National Taiwan University HospitalAcademic, hospital or other
NCT04713670 · 1,200 participants (planned) · Start Mar 10, 2021 · Primary completion Dec 2025
Drug: (A) T-V14; (B) T-V7 and 6 more · For: H. Pylori Infection
Sites: Taipei, Taiwan
- Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori InfectionPivotal-lookingCompleted
Phathom Pharmaceuticals, Inc.Industry
NCT04167670 · 1,046 participants · Start Dec 10, 2019 · Primary completion Mar 10, 2021
Drug: Vonoprazan; Amoxicillin and 2 more · For: Helicobacter Pylori Infection
Sites: Anniston, Alabama; Athens, Alabama; Birmingham, Alabama · 153 sites in all
- Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive EsophagitisPivotal-lookingCompleted
Phathom Pharmaceuticals, Inc.Industry
NCT04124926 · 1,027 participants · Start Oct 28, 2019 · Primary completion Jul 29, 2021
Drug: Vonoprazan; Lansoprazole · For: Erosive Esophagitis
Sites: Anniston, Alabama; Athens, Alabama; Birmingham, Alabama · 157 sites in all
- Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori EradicationPivotal-lookingRecruiting
National Taiwan University HospitalAcademic, hospital or other
NCT07576959 · 990 participants (planned) · Start Apr 8, 2026 · Primary completion Dec 31, 2030
Drug: Bismuth Add-on to Vonoprazan Dual Therapy; Vonoprazan dual therapy · For: HELICOBACTER PYLORI INFECTIONS
Sites: Taipei, Taiwan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea526
- off label use520
- nausea485
- drug ineffective457
- gastrooesophageal reflux disease322
- malaise317
- decreased appetite272
- headache271
- pyrexia253
- abdominal pain upper251
- vomiting242
- product dose omission issue232
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 17 |
| 2017 | 41 |
| 2018 | 90 |
| 2019 | 119 |
| 2020 | 166 |
| 2021 | 426 |
| 2022 | 807 |
| 2023 | 880 |
| 2024 | 1,448 |
| 2025 | 2,182 |
| 2026 | 1,951 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Voquezna (Vonoprazan Fumarate)
2024 spending
$31.3M
Beneficiaries
14,985
37,589 claims
Per beneficiary
$2,085
$20.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $46,258 |
| 2024 | $31,250,586 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Evidence-based clinical practice guidelines for peptic ulcer disease 2020.
Kamada T, Satoh K, Itoh T, et al. · J Gastroenterol 2021 · Practice Guideline, Systematic Review
- Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Chey WD, Mégraud F, Laine L, et al. · Gastroenterology 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Laine L, DeVault K, Katz P, et al. · Gastroenterology 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
Simadibrata DM, Lesmana E, Fass R · J Gastroenterol Hepatol 2024 · Systematic Review, Meta-Analysis
- Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial.
Laine L, Spechler S, Yadlapati R, et al. · Clin Gastroenterol Hepatol 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis.
Kanu JE, Soldera J · World J Gastroenterol 2024 · Meta-Analysis, Systematic Review
Sponsor: Phathom Pharmaceuticals INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.